IQVIA Holdings Inc. Set to Release Q1 Earnings on May 6

IQVIA Holdings Inc. (IQV), with a market capitalization of $25.4 billion, provides essential clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare sectors both in the Americas and globally. The company, headquartered in Durham, North Carolina, operates through three key segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Anticipated Earnings Performance

On May 6, IQV is set to announce its Q1 earnings results. Analysts predict the company will report a profit of $2.39 per share, reflecting a 3.9% increase from the $2.30 per share from the same quarter last year. Notably, IQV has consistently outperformed analysts’ earnings estimates in the last four quarters. In the most recent quarter, the company achieved an earnings per share (EPS) of $2.90, exceeding the consensus estimate by 1.4%.

Future Growth Projections

For the full fiscal year 2025, analysts expect IQV to report an EPS of $10.87, representing a 6.1% increase from the prior fiscal year’s EPS of $10.25. Furthermore, for fiscal 2026, earnings are projected to grow 11.9% year-over-year, reaching $12.16 per share.

Recent Market Performance

Over the past year, IQV’s stock has experienced a significant decline of 38.1%, contrasting sharply with the S&P 500 Index’s modest gain of 3.8% and the Health Care Select Sector SPDR Fund’s (XLV) drop of 4.6% during the same period.

Q4 Results Impact

IQVIA’s stock rose 2.2% following the release of its strong Q4 results on February 6. The company posted a 2.3% year-over-year increase in total revenues, reaching approximately $4 billion, which surpassed analysts’ expectations driven primarily by growth in its Technology & Analytics Solutions segment. However, the Research & Development Solutions and Contract Sales & Medical Solutions segments experienced slight revenue declines due to a softening contract research market and diminished demand. On a positive note, adjusted net income increased by 7.8% year-over-year to $564 million, with an adjusted EPS of $3.12 exceeding consensus estimates by a notable margin.

Analyst Ratings and Price Target

The consensus opinion on IQV’s stock is overwhelmingly positive, earning a “Strong Buy” rating overall. Among the 22 analysts monitoring the stock, 16 have rated it as a “Strong Buy,” one as a “Moderate Buy,” and five as “Holds.” The average price target of $223.36 indicates a potential upside of 58.2% from its current price level.

On the date of publication, Aditya Sarawgi did not hold positions in any of the securities mentioned in this article. All information and data in this report are for informational purposes only. For further details, please view the Barchart Disclosure Policy here.

More news from Barchart

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.